SER-262 is an investigational drug designed to treat Clostridioides difficile infection, a bacterial infection that can cause severe diarrhea and other intestinal issues. It is a microbiome-based therapy that aims to restore the balance of gut bacteria disrupted by the infection. The treatment involves administering a specific formulation of live bacteria to help re-establish a healthy gut environment. SER-262 is being studied in clinical trials to evaluate its safety and effectiveness compared to standard treatments, with the goal of reducing recurrence rates of C. difficile infections.